Empagliflozin protects diabetic pancreatic tissue from damage by inhibiting the activation of the NLRP3/caspase-1/GSDMD pathway in pancreatic β cells: in vitro and in vivo studies

References

• Kharbikar BN, Chendke GS, Desai TA. Modulating the foreign body response of implants for diabetes treatment. Adv Drug Deliv Rev. 2021;174:87–113.
   PubMed Web of Science ®Google Scholar
• Khawandanah J. Double or hybrid diabetes: a systematic review on disease prevalence, characteristics and risk factors. Nutr Diabetes. 2019;9(1):33.
   PubMedGoogle Scholar
• Tuomi T, Santoro N, Caprio S, et al. The many faces of diabetes: a disease with increasing heterogeneity. Lancet. 2014;383:1084–1094.
   PubMed Web of Science ®Google Scholar
• Saeedi P, Petersohn I, Salpea P, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas, 9(th) edition. Diabetes Res Clin Pract. 2019;157:107843.
   PubMed Web of Science ®Google Scholar
• Eizirik DL, Pasquali L, Cnop M. Pancreatic beta-cells in type 1 and type 2 diabetes mellitus: different pathways to failure. Nat Rev Endocrinol. 2020;16:349–362.
   PubMed Web of Science ®Google Scholar
• Quan W, Jo EK, Lee MS. Role of pancreatic beta-cell death and inflammation in diabetes. Diabetes Obes Metab. 2013;15(Suppl 3):141–151.
   PubMedGoogle Scholar
• Saisho Y. beta-cell dysfunction: its critical role in prevention and management of type 2 diabetes. World J Diabetes. 2015;6:109–124.
   PubMed Web of Science ®Google Scholar
• American Diabetes A. 2. classification and diagnosis of diabetes: standards of medical care in diabetes-2019. Diabetes Care. 2019;42:S13–S28.
   PubMed Web of Science ®Google Scholar
• Carre A, Mallone R. Making insulin and staying out of autoimmune trouble: the beta-cell conundrum. Front Immunol. 2021;12:639682.
   PubMed Web of Science ®Google Scholar
• Cookson BT, Brennan MA. Pro-inflammatory programmed cell death. Trends Microbiol. 2001;9(3):113–114.
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Vitale I, Aaronson SA, et al. Molecular mechanisms of cell death: recommendations of the nomenclature committee on cell death 2018. Cell Death Differ. 2018;25:486–541.
   PubMed Web of Science ®Google Scholar
• Wang J, Sahoo M, Lantier L, et al. Caspase-11-dependent pyroptosis of lung epithelial cells protects from melioidosis while caspase-1 mediates macrophage pyroptosis and production of IL-18. PLoS Pathog. 2018;14(5):e1007105.
   PubMed Web of Science ®Google Scholar
• Man SM, Karki R, Kanneganti TD. Molecular mechanisms and functions of pyroptosis, inflammatory caspases and inflammasomes in infectious diseases. Immunol Rev. 2017;277:61–75.
   PubMed Web of Science ®Google Scholar
• Liu P, Zhang Z, Li Y. Relevance of the pyroptosis-related inflammasome pathway in the pathogenesis of diabetic kidney disease. Front Immunol. 2021;12:603416.
   PubMed Web of Science ®Google Scholar
• Zhou R, Tardivel A, Thorens B, et al. Thioredoxin-interacting protein links oxidative stress to inflammasome activation. Nat Immunol. 2010;11(2):136–140.
   PubMed Web of Science ®Google Scholar
• Youm YH, Adijiang A, Vandanmagsar B, et al. Elimination of the NLRP3-ASC inflammasome protects against chronic obesity-induced pancreatic damage. Endocrinology. 2011;152(11):4039–4045.
   PubMed Web of Science ®Google Scholar
• Gao J, Sang M, Zhang X, et al. Miro1-mediated mitochondrial dysfunction under high nutrient stress is linked to NOD-like receptor 3 (NLRP3)-dependent inflammatory responses in rat pancreatic beta cells. Free Radic Biol Med. 2015;89:322–332.
   PubMed Web of Science ®Google Scholar
• Wali JA, Gurzov EN, Fynch S, et al. Activation of the NLRP3 inflammasome complex is not required for stress-induced death of pancreatic islets. PLoS One. 2014;9:e113128.
   PubMed Web of Science ®Google Scholar
• Wang J, Song MY, Lee JY, et al. The NLRP3 inflammasome is dispensable for ER stress-induced pancreatic beta-cell damage in Akita mice. Biochem Biophys Res Commun. 2015;466:300–305.
   PubMed Web of Science ®Google Scholar
• Davies MJ, D’Alessio DA, Fradkin J, et al. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2018;61(12):2461–2498.
   PubMed Web of Science ®Google Scholar
• Grempler R, Thomas L, Eckhardt M, et al. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors. Diabetes Obes Metab. 2012;14:83–90.
   PubMed Web of Science ®Google Scholar
• Seufert J. SGLT2 inhibitors - an insulin-independent therapeutic approach for treatment of type 2 diabetes: focus on canagliflozin. Diabetes Metab Syndr Obes. 2015;8:543–554.
   PubMed Web of Science ®Google Scholar
• Shubrook JH, Bokaie BB, Adkins SE. Empagliflozin in the treatment of type 2 diabetes: evidence to date. Drug Des Devel Ther. 2015;9:5793–5803.
   PubMed Web of Science ®Google Scholar
• Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–2128.
   PubMed Web of Science ®Google Scholar
• Jurczak MJ, Saini S, Ioja S, et al. SGLT2 knockout prevents hyperglycemia and is associated with reduced pancreatic beta-cell death in genetically obese mice. Islets. 2018;10:181–189.
   PubMed Web of Science ®Google Scholar
• Jin J, Jin L, Luo K, et al. Effect of empagliflozin on tacrolimus-induced pancreas islet dysfunction and renal injury. Am J Transplant. 2017;17:2601–2616.
   PubMed Web of Science ®Google Scholar
• Li T, Quan H, Zhang H, et al. Silencing cyclophilin A improves insulin secretion, reduces cell apoptosis, and alleviates inflammation as well as oxidant stress in high glucose-induced pancreatic beta-cells via MAPK/NF-kb signaling pathway. Bioengineered. 2020;11:1047–1057.
   PubMed Web of Science ®Google Scholar
• Wei J, Yan T, Liang Y. Targeting TRAF3IP2 alleviates high glucose-induced cardiomyocyte inflammation and apoptosis. Drug Dev Res. 2021; 10.1002/ddr.21856.
   Web of Science ®Google Scholar
• Wang W, He D, Chen J, et al. Circular RNA Plek promotes fibrogenic activation by regulating the miR-135b-5p/TGF-betaR1 axis after spinal cord injury. Aging (Albany NY). 2021;13:13211–13224.
   PubMedGoogle Scholar
• Huang Y, Zhen J, Liu T, et al. Defective insulin maturation in patients with type 2 diabetes. Eur J Endocrinol. 2021;185:565–576.
   PubMed Web of Science ®Google Scholar
• Liu T, Cui L, Xue H, et al. Telmisartan potentiates insulin secretion via ion channels, independent of the AT1 RECEptor and PPARgamma. Front Pharmacol. 2021;12:739637.
   PubMed Web of Science ®Google Scholar
• Lei M, Zhao K, Hua W, et al. An in vivo study of the effect of c-Jun on intervertebral disc degeneration in rats. Bioengineered. 2021;12:4320–4330.
   PubMed Web of Science ®Google Scholar
• Li J, Huang Z, Li B, et al. Mobilization of transplanted bone marrow mesenchymal stem cells by erythropoietin facilitates the reconstruction of segmental bone defect. Stem Cells Int. 2019;2019:5750967.
   PubMed Web of Science ®Google Scholar
• Nolan CJ, Damm P, Prentki M. Type 2 diabetes across generations: from pathophysiology to prevention and management. Lancet. 2011;378:169–181.
   PubMed Web of Science ®Google Scholar
• Chen X, Zhang D, Li Y, et al. NLRP3 inflammasome and IL-1beta pathway in type 2 diabetes and atherosclerosis: friend or foe? Pharmacol Res. 2021;173:105885.
   PubMed Web of Science ®Google Scholar
• Yu Y, Chen D, Zhao Y, et al. Melatonin ameliorates hepatic steatosis by inhibiting NLRP3 inflammasome in db/db mice. Int J Immunopathol Pharmacol. 2021;35:20587384211036819.
   Web of Science ®Google Scholar
• Zeng W, Wu D, Sun Y, et al. The selective NLRP3 inhibitor MCC950 hinders atherosclerosis development by attenuating inflammation and pyroptosis in macrophages. Sci Rep. 2021;11:19305.
   PubMed Web of Science ®Google Scholar
• Cai J, Yang J, Chen X, et al. Melatonin ameliorates trimethyltin chloride-induced cardiotoxicity: the role of nuclear xenobiotic metabolism and Keap1-Nrf2/ARE axis-mediated pyroptosis. Biofactors. 2021; 10.1002/biof.1787.
   Web of Science ®Google Scholar
• Platt TL, Beckett TL, Kohler K, et al. Obesity, diabetes, and leptin resistance promote tau pathology in a mouse model of disease. Neuroscience. 2016;315:162–174.
   PubMed Web of Science ®Google Scholar
• Wu YR, Shi XY, Ma CY, et al. Liraglutide improves lipid metabolism by enhancing cholesterol efflux associated with ABCA1 and ERK1/2 pathway. Cardiovasc Diabetol. 2019;18:146.
   PubMed Web of Science ®Google Scholar
• Flick AC, Ding HX, Leverett CA, et al. Synthetic approaches to the 2014 new drugs. Bioorg Med Chem. 2016;24:1937–1980.
   PubMed Web of Science ®Google Scholar
• Cheng ST, Chen L, Li SY, et al. The effects of empagliflozin, an SGLT2 inhibitor, on pancreatic beta-cell mass and glucose homeostasis in type 1 diabetes. PLoS One. 2016;11:e0147391.
   PubMed Web of Science ®Google Scholar
• Ruan D, Liu Y, Wang X, et al. miR-149-5p protects against high glucose-induced pancreatic beta cell apoptosis via targeting the BH3-only protein BIM. Exp Mol Pathol. 2019;110:104279.
   PubMed Web of Science ®Google Scholar
• Skoczek D, Dulak J, Kachamakova-Trojanowska N. Maturity onset diabetes of the young-new approaches for disease modelling. Int J Mol Sci. 2021;22(14):7553.
   Web of Science ®Google Scholar
• Johnson JD. On the causal relationships between hyperinsulinaemia, insulin resistance, obesity and dysglycaemia in type 2 diabetes. Diabetologia. 2021;64:2138–2146.
   PubMed Web of Science ®Google Scholar
• Chang TT, Lin LY, Chen JW. A novel resolution of diabetes: C-C Chemokine Motif Ligand 4 is a common target in different types of diabetes by protecting pancreatic islet cell and modulating inflammation. Front Immunol. 2021;12:650626.
   PubMed Web of Science ®Google Scholar
• Kaneto H, Obata A, Kimura T, et al. Beneficial effects of sodium-glucose cotransporter 2 inhibitors for preservation of pancreatic beta-cell function and reduction of insulin resistance. J Diabetes. 2017;9:219–225.
   PubMed Web of Science ®Google Scholar
• Pei P, Yao X, Jiang L, et al. Inorganic arsenic induces pyroptosis and pancreatic beta cells dysfunction through stimulating the IRE1alpha/TNF-alpha pathway and protective effect of taurine. Food Chem Toxicol. 2019;125:392–402.
   PubMed Web of Science ®Google Scholar
• Ye Y, Bajaj M, Yang HC, et al. SGLT-2 inhibition with dapagliflozin reduces the activation of the Nlrp3/ASC inflammasome and attenuates the development of diabetic cardiomyopathy in mice with type 2 diabetes. Further augmentation of the effects with Saxagliptin, a DPP4 inhibitor. Cardiovasc Drugs Ther. 2017;31:119–132.
   PubMed Web of Science ®Google Scholar
• Daems C, Welsch S, Boughaleb H, et al. Early treatment with empagliflozin and GABA improves beta-cell mass and glucose tolerance in streptozotocin-treated mice. J Diabetes Res. 2019;2019:2813489.
   PubMed Web of Science ®Google Scholar
• Al Jobori H, Daniele G, Adams J, et al. Empagliflozin treatment is associated with improved beta-cell function in type 2 diabetes mellitus. J Clin Endocrinol Metab. 2018;103:1402–1407.
   PubMed Web of Science ®Google Scholar